[关于新开发抗结核药物用于耐多药结核病的考虑]。

Kekkaku : [Tuberculosis] Pub Date : 2014-11-01

Toru Mori, Kenji Ogawa, Eriko Shigeto, Tadao Shimao, Katsuhiro Suzuki, Kazunari Tsuyuguchi, Hideaki Nagai, Tomoshige Matsumoto, Satoshi Mitarai, Takashi Yoshiyama

{"title":"[关于新开发抗结核药物用于耐多药结核病的考虑]。","authors":"Toru Mori, Kenji Ogawa, Eriko Shigeto, Tadao Shimao, Katsuhiro Suzuki, Kazunari Tsuyuguchi, Hideaki Nagai, Tomoshige Matsumoto, Satoshi Mitarai, Takashi Yoshiyama","doi":"","DOIUrl":null,"url":null,"abstract":"We, group of tuberculosis experts, made discussions over how to improve the quality of treatment of multidrug resistant tuberculosis using a newly developed anti-tuberculosis drug, and at the same time, how to prevent the disadvantages of the treated patients and also that of persons who would be infected with newly produced drug-resistant bacilli, by preventing the emergence of resistance to the new drug. A series of proposals are made.","PeriodicalId":17997,"journal":{"name":"Kekkaku : [Tuberculosis]","volume":"89 11","pages":"813-5"},"PeriodicalIF":0.0000,"publicationDate":"2014-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Considerations on uses of newly developed anti-tuberculosis drugs for multi-drug resistant tuberculosis].\",\"authors\":\"Toru Mori, Kenji Ogawa, Eriko Shigeto, Tadao Shimao, Katsuhiro Suzuki, Kazunari Tsuyuguchi, Hideaki Nagai, Tomoshige Matsumoto, Satoshi Mitarai, Takashi Yoshiyama\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We, group of tuberculosis experts, made discussions over how to improve the quality of treatment of multidrug resistant tuberculosis using a newly developed anti-tuberculosis drug, and at the same time, how to prevent the disadvantages of the treated patients and also that of persons who would be infected with newly produced drug-resistant bacilli, by preventing the emergence of resistance to the new drug. A series of proposals are made.\",\"PeriodicalId\":17997,\"journal\":{\"name\":\"Kekkaku : [Tuberculosis]\",\"volume\":\"89 11\",\"pages\":\"813-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kekkaku : [Tuberculosis]\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kekkaku : [Tuberculosis]","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

我们结核病专家小组讨论了如何使用新开发的抗结核药物提高耐多药结核病的治疗质量，同时如何通过防止新产生的耐药杆菌的出现，防止治疗患者和可能感染新产生的耐药杆菌的人的不利条件。提出了一系列建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[Considerations on uses of newly developed anti-tuberculosis drugs for multi-drug resistant tuberculosis].

We, group of tuberculosis experts, made discussions over how to improve the quality of treatment of multidrug resistant tuberculosis using a newly developed anti-tuberculosis drug, and at the same time, how to prevent the disadvantages of the treated patients and also that of persons who would be infected with newly produced drug-resistant bacilli, by preventing the emergence of resistance to the new drug. A series of proposals are made.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Kekkaku : [Tuberculosis]

自引率

0.00%

发文量

期刊最新文献

[Surgical treatment of tuberculosis]. [Pulmonary fibrosis]. [CLINICAL ANALYSIS OF 115 PULMONARY TUBERCULOSIS PATIENTS WITH SPUTUM SMEAR-NEGATIVE]. [ESTIMATION OF POSITIVE RATES OF INTERFERON-GAMMA RELEASE ASSAY BY AGE GROUP IN JAPAN]. [COMPARISON OF TUBERCULOSIS SURVEILLANCE SYSTEMS IN JAPAN AND LOW-INCIDENCE COUNTRIES: INSTITUTIONAL DESIGN].